TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11/2/22 18:42 | 10/31/22 | BMRN | Biomarin Pharmaceutical Inc | DE | Health | Drug | Pharmaceutical Preparations | Alles Mark J | CA | D | P | 314 | 86.75 | 0 | 4 | 50 | 11 | D | |||||||||||||||
6/21/21 21:14 | 6/21/21 | TPTX | Turning Point Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Alles Mark J | CA | D | P | 163 | 81.34 | 0 | 2 | New | 2 | D | |||||||||||||||
5/13/20 17:05 | 5/13/20 | SYRS | Syros Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Alles Mark J | MA | D | P | 89 | 8.86 | 0 | 10 | New | 10 | D | |||||||||||||||
5/17/18 16:08 | 5/9/18 | CELG | Celgene Corp /de/ | DE | Health | Drug | Pharmaceutical Preparations | Alles Mark J | NJ | DO | CEO,CB | P.d | 100 | 82.60 | 0 | 1 | 1 | 193 | D | ||||||||||||||
2/8/18 16:47 | 2/8/18 | CELG | Celgene Corp /de/ | DE | Health | Drug | Pharmaceutical Preparations | Alles Mark J | NJ | DO | See Rema | P | 300 | 91.90 | 0 | 3 | 2 | 185 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |